Replimune Group Inc. | Investor Relations
The Investor Relations website contains information about Replimune Group Inc.'s business for stockholders, potential investors, and financial analysts.
ir.replimune.comHere’s the latest publicly reported news on Replimune Limited (REPL) as of now.
-
FDA update on RP1: Replimune has faced regulatory hurdles around RP1 in combination with nivolumab for advanced melanoma. In 2025-2026 coverage, the FDA issued a complete response letter (CRL) citing design and population heterogeneity concerns in the IGNYTE program, with regulators indicating a need for a revised path forward. This has weighed on expectations for near-term approval.[2][4][8]
-
PDUFA timeline and progress: In early 2026 coverage, the company referenced a PDUFA target action date around April 10, 2026 for RP1 resubmission, and ongoing discussions about whether accelerated approval could form a viable path forward, given regulatory feedback. This timeline has been a focal point for investors and analysts.[1][5]
-
Financial and corporate updates: Replimune continued to provide quarterly financial updates and corporate updates in 2025–2026, including cash runway considerations and debt facilities tied to potential future commercialization scenarios. Some reports note substantial cash, ongoing losses, and the potential need for additional funding depending on regulatory outcomes.[3][5][6][1][2]
-
Market and investor sentiment: Stock market coverage in 2025 highlighted significant volatility tied to regulatory decisions, with reports that the stock surged on certain regulatory milestones and then retraced after the CRL and related feedback. Commentary from analysts has been mixed, balancing the promise of RP1 against regulatory uncertainties.[4][3]
-
Additional program updates: Replimune’s other programs (e.g., RP2 for different indications and other IGNYTE-related studies) have continued to be discussed in investor materials, though primary focus remains on RP1’s regulatory path and potential approvals.[9][1]
Would you like a concise timeline of key regulatory events for RP1, with dates and what the FDA communication indicated, or a summary of current investor sentiment and potential pathways forward? I can also pull the latest official press releases from Replimune’s investor relations page if you’d like direct source links.